Hereditary Spastic Paraplegia 11 (SPG11): Comprehensive Research Report

1. Disease Information

Overview

Hereditary Spastic Paraplegia 11 (SPG11) is an autosomal recessive, complex (complicated) form of hereditary spastic paraplegia caused by biallelic loss-of-function variants in the SPG11 gene, encoding the protein spatacsin. It is the most common cause of autosomal recessive HSP overall and the most frequent cause of "HSP with thin corpus callosum" (ARHSP-TCC), accounting for roughly 19–31% of autosomal recessive HSP cases, up to 30–50% of complex autosomal recessive HSP, and up to 59–70% of cases when both intellectual impairment and thin corpus callosum are present, but fewer than 10% of "pure" HSP cases (NCBI GeneReviews, Spastic Paraplegia 11).

Clinically, SPG11 presents with progressive spastic paraparesis of the lower limbs combined with a broad multisystem neurodegenerative syndrome: mild intellectual disability/learning difficulty in childhood and/or progressive cognitive decline, axonal peripheral neuropathy (reported in >80% of cases), pseudobulbar signs (dysarthria, hypomimia), and brisk upper-limb reflexes. Less frequent findings include cerebellar signs (found in over half of patients, per ScienceDirect topic overview), retinal/macular degeneration (Kjellin syndrome), pes cavus, scoliosis, tremor and parkinsonism, and, uncommonly, epilepsy. The disease was historically also described under names such as Nakamura-Osame syndrome.

Key Identifiers

Table (click to expand)

Resource	Identifier
OMIM (phenotype)	604360 — Spastic Paraplegia 11, Autosomal Recessive (OMIM:604360)
OMIM (gene)	610844 — SPG11, Vesicle Trafficking Associated, Spatacsin (OMIM:610844)
Gene	SPG11 (formerly KIAA1840), chromosome 15q21.1
Orphanet	ORPHA:2822 — Autosomal recessive spastic paraplegia type 11 (Orphanet)
MONDO	MONDO term for "hereditary spastic paraplegia 11" (mapped from OMIM 604360; used by GARD/NORD, GARD entry, NORD MONDO page)
GeneReviews	Spastic Paraplegia 11 (NBK1210)
ICD-10	G11.4 (Hereditary spastic paraplegia) — generic code; no SPG11-specific ICD-10/11 code exists

Synonyms

Nakamura-Osame syndrome
Autosomal recessive hereditary spastic paraplegia with thin corpus callosum (ARHSP-TCC)
Spastic paraplegia-intellectual disability-thin corpus callosum syndrome
Kjellin syndrome (when central retinal degeneration is prominent)
ALS5 and CMT2X are allelic disorders (see §4)

Data Source Type

Information below is aggregated from disease-level resources (OMIM, Orphanet, GeneReviews, MONDO) and case-series/cohort literature (typically tens to low hundreds of patients), rather than large-scale EHR/claims data, reflecting SPG11's rarity.

2. Etiology

Disease Causal Factors

SPG11 is a monogenic, purely genetic disease. It is caused by biallelic (homozygous or compound heterozygous) loss-of-function variants in SPG11. GeneReviews states that "most pathogenic variants identified to date in SPG11 predict truncation of the protein, demonstrating that pathogenicity results from loss of spatacsin function" (NBK1210). More than 100 distinct mutations have been catalogued across the 15q21.1 locus, including nonsense, frameshift (small insertions/deletions), splice-site, and exon-level or larger deletion/duplication variants; approximately 10–20% of disease alleles are exon-sized or larger structural rearrangements not detectable by sequencing alone (GeneReviews; ScienceDirect).

The founding gene-identification study, Stevanin et al. (2007, Nature Genetics 39:366–372, DOI 10.1038/ng1980), analyzed 12 autosomal recessive HSP-with-thin-corpus-callosum families linked to the SPG11 locus on chromosome 15 and identified ten mutations — nonsense or frameshift-causing insertions/deletions — in a previously uncharacterized gene expressed ubiquitously in the nervous system, most prominently in cerebellum, cerebral cortex, hippocampus, and pineal gland (Nature Genetics).

Genotype–Phenotype Correlation

Missense and splice-site variants (which may retain partial protein function) are associated with later onset and milder disease severity, whereas truncating (nonsense/frameshift) variants — the majority of pathogenic alleles — produce the more typical earlier-onset, severe phenotype (GeneReviews NBK1210).

Risk Factors

Genetic: Biallelic pathogenic SPG11 variants are both necessary and sufficient — this is a fully penetrant Mendelian recessive disease, not a susceptibility-locus condition. There is no meaningful "risk allele" concept beyond carrier status.
Consanguinity: Most originally described families derive from populations/regions where consanguinity is common (Mediterranean basin, Middle East, North Africa), though the disease has now been reported worldwide (GeneReviews).
Founder effects: Regional recurrent variants have been reported in various populations, consistent with founder mutations, though SPG11 mutational spectrum is broadly heterogeneous rather than dominated by one global founder allele.
De novo occurrence: Rare; at least one reported case involved one variant inherited from a carrier parent and a second occurring de novo in the proband (GeneReviews).
Environmental/lifestyle factors: None established — SPG11 has no known environmental, infectious, dietary, or occupational risk-factor contribution. This distinguishes it from complex/multifactorial neurodegenerative diseases.

Protective Factors

No genetic or environmental protective factors have been described. There is no evidence of modifier alleles ameliorating disease course in the literature reviewed, though variability in age of onset (1–60 years) and severity even among individuals with the same genotype suggests unidentified modifiers or stochastic factors may exist.

Gene–Environment Interactions

None established; SPG11 pathogenesis is driven by loss of spatacsin protein function rather than gene–environment interplay.

3. Phenotypes

SPG11 produces a multisystem, progressive clinical picture. Below, phenotypes are grouped with suggested HPO terms, onset/frequency where reported, and progression pattern.

Motor/Corticospinal Phenotypes

Table (click to expand)

Phenotype	HPO term (suggested)	Frequency/Notes
Progressive spastic paraparesis (lower-limb spasticity and weakness)	HP:0007256 (progressive spasticity), HP:0002061 (spastic paraparesis)	Core feature, essentially 100%
Hyperreflexia (upper limb)	HP:0001347	Common
Extensor plantar responses (Babinski sign)	HP:0003487	Common
Pseudobulbar signs — dysarthria, hypomimia	HP:0001260 (dysarthria), HP:0000338 (hypomimia)	Frequent
Lower motor neuron/muscle wasting (ALS5-like presentation)	HP:0003202 (muscle wasting)	Reported, especially in later stage/motor-predominant presentations

Wheelchair dependence typically develops 1–2 decades after disease onset ("Most affected individuals become wheelchair bound one or two decades after disease onset," per GeneReviews NBK1210).

Cognitive/Behavioral Phenotypes

Cognitive impairment/intellectual disability, present in 80–100% of patients according to a recent clinical-genetic-imaging cohort study (PMC10743703). Presents either as childhood learning difficulty or as progressive cognitive decline/dementia in later life.
Specific deficits documented: severe short-term memory impairment, emotional lability, childish behavior, reduced verbal fluency, and attention deficits indicative of executive dysfunction (GeneReviews NBK1210).
HPO suggestions: HP:0001249 (Intellectual disability), HP:0002354 (Memory impairment), HP:0000737 (Irritability/emotional lability), HP:0000708 (Behavioral abnormality), HP:0002088 (Abnormal executive function — via broader cognitive term sets).
A neuropsychology/MRI correlation study of 16 SPG11 patients found reaction times correlated significantly with disease progression, with long-term follow-up testing in a subset of 7 patients (PMC9336101).

Peripheral Neuropathy

Axonal sensorimotor peripheral neuropathy reported in >80% of individuals (GeneReviews). It commonly emerges later in the disease course, distinct from the early cognitive/spastic features, and can progress to a pure motor neuropathy or ALS5-like/CMT2X-like presentation in some patients.
HPO term: HP:0009830 (Peripheral neuropathy), HP:0007002 (Axonal loss).

Ophthalmologic/Retinal Phenotype (Kjellin Syndrome)

Central retinal degeneration with bilateral retinal flecks (resembling Stargardt disease/fundus flavimaculatus) constitutes the eponymous "Kjellin syndrome" subtype (PMID:19194956; PMID:21035867). Notably, retinal changes are typically only observed once paraplegia has become apparent, and may be clinically silent, requiring dedicated fundus examination and OCT/electroretinography for detection (case example in late-onset diagnosis: PMID:38613257).
HPO terms: HP:0000546 (Retinal degeneration), HP:0007754 (Macular dystrophy).

Cerebellar and Movement Disorder Phenotypes

Cerebellar signs (dysarthria, dysmetria, dysdiadochokinesia, intention tremor, nystagmus, gait ataxia) reported in over half of patients (ScienceDirect overview).
A subset present with extrapyramidal features — focal dystonia, tremor, and juvenile/early-onset parkinsonism with variable levodopa responsiveness, reported particularly in SPG7 and SPG11 (PMC10689114; case report SPG11 Presenting with Tremor).
HPO terms: HP:0001251 (Ataxia), HP:0000639 (Nystagmus), HP:0001300 (Parkinsonism), HP:0001337 (Tremor).

Musculoskeletal

Pes cavus (HP:0001761) and scoliosis (HP:0002650) reported as less-frequent features.

Other/Less Frequent

Seizures/epilepsy: uncommon in SPG11 — a feature that helps distinguish it from some other complex HSP subtypes (tremorjournal search summary; OMIM:618876 is a distinct, unrelated progressive myoclonic epilepsy entry, not SPG11-specific). HPO: HP:0001250 (Seizure).
Sphincter/bladder disturbance — urinary urgency, requiring urodynamic evaluation (GeneReviews).

Age of Onset and Progression Characteristics

Onset is highly variable: 1–31 years in most series, rarely as late as age 60 (GeneReviews). A recent cohort placed mean age of onset at 14.3 years (range 4–36 years) (search summary of Orphanet/cohort data).
Progressive disease course — not episodic or relapsing-remitting. Most patients develop the "complete" complex phenotype within about a decade of first symptoms.
A recent large case-report/series review compiling 339 SPG11 cases found: spasticity, hyperreflexia, gait disturbance, cognitive decline, decreased vision, epilepsy, and scoliosis as reported findings, with brain MRI showing thin corpus callosum in 173/190 cases with available imaging data (91%), periventricular white matter changes in 130/158 (82%), and cortical atrophy in 55/107 (51%) (Frontiers in Neurology, 2023).

Quality of Life

Specific validated QoL instrument data (EQ-5D, SF-36) for SPG11 were not identified in this search; broader HSP QoL literature documents substantial impact on mobility-related and cognitive domains of daily functioning given the combination of progressive lower-limb disability with wheelchair dependence and cognitive decline, but disease-specific quantitative QoL studies for SPG11 were not located and should be flagged as not established / data-limited in a KB entry.

4. Genetic/Molecular Information

Causal Gene

Gene: SPG11 (HGNC symbol SPG11; former alias KIAA1840)
Locus: chromosome 15q21.1
Protein: spatacsin
OMIM gene entry: 610844 (OMIM:610844)
OMIM phenotype entry: 604360, "Spastic Paraplegia 11, Autosomal Recessive" (OMIM:604360)

Pathogenic Variants

Variant types: The mutational spectrum spans nonsense, frameshift (small indels), splice-site, missense, and exon-level/larger genomic deletions or duplications. More than 100 distinct mutations are catalogued.
Variant classification (ACMG/AMP): The vast majority of disease-causing alleles are classified pathogenic/likely pathogenic in ClinVar on the basis of predicted protein truncation (see ClinVar records, e.g. RCV000001168, c.6100C>T p.Arg2034Ter; RCV000034200, c.2834+1G>T splice variant).
Detection rates: Sequence analysis identifies ~81% of pathogenic alleles; deletion/duplication (copy-number) analysis is needed to identify the remaining ~19% (GeneReviews).
Functional consequence: Loss of function — this is the unambiguous, well-established mechanism (truncating variants predominate; missense/splice variants associated with milder, later-onset phenotypes retain partial function).
Somatic vs. germline: Exclusively germline in SPG11-HSP (this is not a cancer-predisposition or somatic-mosaicism-driven disease in its classic presentation).

Modifier Genes

No validated modifier genes have been established for SPG11 severity or age of onset in the literature surveyed. Genotype (truncating vs. missense/splice) is the main documented modifier of phenotype severity.

Allelic Disorders (Same Gene, Different Phenotypes)

Biallelic SPG11 pathogenic variants cause a spectrum of motor neuron degeneration phenotypes regardless of variant type, including: - Pure or complex hereditary spastic paraplegia (classic SPG11) - Autosomal recessive juvenile-onset amyotrophic lateral sclerosis type 5 (ALS5) - Autosomal recessive Charcot-Marie-Tooth disease type 2X (CMT2X) - An association with multiple sclerosis has also been reported

(Source: MalaCards/OMIM aggregation; GeneReviews NBK1210)

Epigenetic Information

A 2025 transcriptomic study ("Transcriptomic analysis reinforces the implication of spatacsin in neuroinflammation and neurodevelopment," Scientific Reports, DOI link) reinforces links between spatacsin loss and dysregulated neurodevelopmental and neuroinflammatory transcriptional programs, though this is transcriptomic rather than classical epigenetic (methylation/histone) data specifically.

Chromosomal Abnormalities

Not typically a large-scale chromosomal disorder; disease-causing lesions are gene-level (point mutations, indels) or exon-level deletions/duplications within SPG11, detectable via targeted deletion/duplication (CNV) analysis, exome, or genome sequencing rather than karyotype/FISH.

5. Environmental Information

Environmental factors: None established as causal or modifying for SPG11 — it is a purely monogenic disease.
Lifestyle factors: No established role; general supportive-care lifestyle measures (physiotherapy, activity maintenance) affect symptom management, not underlying etiology.
Infectious agents: None implicated.

6. Mechanism / Pathophysiology

Protein Function and the AP-5 Complex

Spatacsin functions as an accessory protein of adaptor protein complex 5 (AP-5), working together with spastizin (the SPG15 gene product) and the AP-5 core subunit AP5Z1. This AP-5–SPG11–SPG15 complex is implicated in endosome-to-trans-Golgi-network recycling of the cation-independent mannose-6-phosphate receptor (CI-MPR), a receptor essential for delivering lysosomal hydrolases to lysosomes. Loss of SPG11, SPG15, or AP5Z1 causes CI-MPR to accumulate abnormally in early endosomes (Molecular Biology of the Cell, PMC; J. Cell Biology, Rag GTPases/PI3P recruitment of AP-5/SPG11/SPG15).

A 2025 structural biology paper resolved the structural basis for membrane remodeling by the AP5–SPG11–SPG15 complex (Nature Structural & Molecular Biology, DOI link), and a 2023 PLOS Biology study showed spatacsin regulates the directionality of lysosome trafficking by promoting degradation of its partner AP5Z1 — spastizin and AP5Z1 regulate tubular lysosome formation and its anterograde/retrograde trafficking via kinesin KIF13A and dynein/dynactin p150Glued, respectively (PMID:37871017; PLOS Biology).

Causal Chain: Endolysosomal Dysfunction → Lipid Accumulation → Axonal Degeneration

Trigger: Biallelic loss-of-function SPG11 variants → loss of spatacsin protein.
Molecular consequence: Impaired AP-5-mediated endosomal/lysosomal receptor trafficking; failure of autophagic lysosome reformation (ALR) — the process by which lysosomes are recycled from autolysosomes. In Spg11 knockout mice, autophagic flux studies show diminished lysosome tubulation events in starved knockout MEFs, and lysosome numbers decrease in knockout brain neurons (PMID:33618608; PLOS Genetics PMC4540459).
Cellular consequence: Lysosomal depletion and impaired autophagic clearance leads to progressive accumulation of autofluorescent lipofuscin-like material and lysosomal proteins (LAMP1, p62) within neurons — direct in vivo evidence for lysosome depletion and impaired autophagic clearance was demonstrated in Spg11-knockout mice (PLOS Genetics, PMC4540459).
Lipid handling defect: Loss of spatacsin function alters lysosomal lipid clearance, with accumulation of gangliosides and cholesterol, altering membrane cholesterol levels and disrupting calcium homeostasis; this impairs neurite formation and dysregulates GSK3β signaling — establishing a mechanistic route from lysosomal dysfunction to structural neuronal damage (PMID:28237315, "Loss of spatacsin function alters lysosomal lipid clearance leading to upper and lower motor neuron degeneration"; corroborated by GeneReviews mechanistic summary).
Axonal instability: Independent of lipid/lysosomal pathways, spatacsin loss causes axonal instability via downregulation of acetylated tubulin and reduced anterograde vesicle trafficking, indicating impaired axonal transport — demonstrated in "Dysfunction of spatacsin leads to axonal pathology in SPG11-linked hereditary spastic paraplegia" (PMID:24794856; PMC4140466).
Mitochondrial involvement: Axon-specific mitochondrial pathology has been documented in SPG11 alpha motor neurons ("Axon-Specific Mitochondrial Pathology in SPG11 Alpha Motor Neurons," Frontiers in Neuroscience), suggesting a convergent axonal energy-metabolism deficit contributing to distal axonopathy.
Neurodevelopmental component: A 2020 Brain review, "Janus-faced spatacsin (SPG11): involvement in neurodevelopment and multisystem neurodegeneration" (Oxford Academic), frames spatacsin as having a dual role — contributing to normal neurodevelopment as well as being required to prevent neurodegeneration, potentially explaining the combination of static (cognitive/structural, e.g., thin corpus callosum) and progressive (spasticity, neuropathy) features. A 2025 transcriptomic study reinforces this dual neuroinflammatory/neurodevelopmental signature (Scientific Reports).
Final common pathway / clinical manifestation: Progressive degeneration of the long corticospinal tract axons (upper motor neuron), together with lower motor neuron and peripheral axon degeneration, and cortical/cerebellar neuron loss (including Purkinje cell loss, seen in mouse models), produces the combined spastic paraparesis, cognitive decline, cerebellar, and peripheral neuropathy phenotype.

Suggested Ontology Terms for Pathophysiology Nodes

GO Biological Process: GO:0016240 (autophagosome membrane docking)/GO:0000045 (autophagosome assembly); GO:0007032 (endosome organization); GO:0016082 (synaptic vesicle priming — for anterograde transport); a general "axonal transport" GO term (GO:0008088, axo-dendritic transport); GO:0032418 (lysosome localization).
GO Cellular Component: GO:0005764 (lysosome); GO:0005768 (endosome); GO:0030425 (dendrite)/GO:0030424 (axon).
CL (cell type): CL:0000030 (glutamatergic upper motor/pyramidal corticospinal neuron), CL:0000100 (motor neuron), CL:0000121 (Purkinje cell — per mouse model loss), CL:0002573 (Schwann cell — peripheral neuropathy arm).
CHEBI: CHEBI:16113 (cholesterol), CHEBI:24404 (ganglioside class) — for the lipid-accumulation arm.

Molecular Profiling / Omics

Transcriptomics: 2025 Scientific Reports transcriptomic analysis in SPG11 models supports neuroinflammatory and neurodevelopmental gene expression signatures (Scientific Reports).
iPSC-based cellular models: SPG11-patient-derived iPSC cortical neurons (and a CRISPR-Cas9-generated SPG11 knockout line) show shorter, less complex neurites than controls, membrane-bound structures within neuronal processes, and impaired organelle transport/lack of synaptic vesicle movement — used as a drug-screening platform ("Tideglusib Rescues Neurite Pathology of SPG11 iPSC Derived Cortical Neurons," PMC6291617), where the GSK3β inhibitor tideglusib reversed neurite defects — directly connecting the GSK3β-signaling mechanistic node to a candidate small-molecule intervention.

Single-Cell / Spatial / Multi-omics

Dedicated single-cell or spatial transcriptomic datasets specific to SPG11 patient tissue were not identified in this search — model-system (mouse, zebrafish, iPSC) transcriptomic/proteomic data are the primary molecular-profiling resources currently available.

7. Anatomical Structures Affected

Organ/System Level

Primary: Central nervous system — corticospinal tracts (long motor axons), cerebral cortex, corpus callosum, cerebellum, brainstem, basal ganglia, retina.
Secondary: Peripheral nervous system (peripheral nerves — axonal sensorimotor neuropathy); musculoskeletal system (secondary contractures, scoliosis, pes cavus from chronic spasticity); genitourinary system (neurogenic bladder/sphincter disturbance).
Body systems involved: Nervous system (primary), musculoskeletal, sensory (visual), genitourinary.

Tissue/Cell Level

Upper motor neurons of the corticospinal tract (long-axon pyramidal neurons)
Lower motor neurons (in ALS5-like/motor-neuropathy presentations)
Peripheral (sensory and motor) axons — axonal, not primarily demyelinating, neuropathy
Cerebellar Purkinje cells (documented loss in mouse models — PMID:33618608)
Cortical neurons
Retinal pigment epithelium/photoreceptors (macular dystrophy in Kjellin syndrome)

Suggested UBERON terms: UBERON:0002240 (spinal cord), UBERON:0002298 (brainstem), UBERON:0002037 (cerebellum), UBERON:0002336 (corpus callosum), UBERON:0000966 (retina), UBERON:0001017 (central nervous system), UBERON:0000010 (peripheral nervous system).

Subcellular Level

Lysosomes/autolysosomes (GO:0005764)
Endosomes (GO:0005768)
Axonal cytoskeleton (microtubules — acetylated tubulin pool)
Mitochondria (axon-specific mitochondrial pathology)

Localization/Lateralization

Bilateral/symmetric involvement; corpus callosum thinning is diffuse but classically most pronounced at the rostral body/anterior midbody.

8. Temporal Development

Onset

Typical onset: infancy through adolescence, range 1–31 years, rarely up to age 60 (GeneReviews).
Mean age of onset reported as 14.3 years (range 4–36) in one cohort (search summary, Orphanet/cohort data).
Onset pattern: insidious, gradually progressive — not acute or episodic.

Progression

Chronic, progressive disease course (not relapsing-remitting).
Most patients develop the "complete" complex phenotype within roughly a decade of first symptoms.
Wheelchair dependence typically develops 1–2 decades after onset (GeneReviews).
Cognitive decline and motor neuropathy tend to manifest and progress later in the disease course relative to the initial spasticity/cognitive-learning-difficulty presentation.
Retinal changes (Kjellin phenotype) generally appear after paraplegia is established, not as a presenting sign.

Patterns

No spontaneous remission is described; this is a monotonically progressive neurodegenerative disorder.
No clearly defined "critical therapeutic window" has been established in the literature, though earlier diagnosis/intervention with symptomatic and rehabilitative therapy is generally advocated.

9. Inheritance and Population

Epidemiology

Overall HSP prevalence: highly variable by geography, ranging from ~1/11,000 to 1/77,000 in Europe; broader estimates of 1–10 per 100,000 depending on region (Orphanet; GeneReviews).
SPG11-specific incidence: 0.35 per 100,000 people, accounting for 19–31% of autosomal recessive HSP (Frontiers in Neurology 2023 cohort summary).
Calculated SPG11 prevalence: GeneReviews estimates approximately 1.25 per 100,000 by applying the 19–31% AR-HSP fraction to overall AR-HSP prevalence figures (NBK1210).
A formal integrated epidemiological modeling study specifically estimated global incidence/prevalence for SPG4, SPG7, SPG11, and SPG15 (PMC8944001) — useful for cross-referencing model-based prevalence estimates against the simpler fraction-based GeneReviews estimate.

Inheritance Pattern

Autosomal recessive.
Recurrence risk: each sibling of an affected individual has a 25% chance of being affected, 50% chance of being an unaffected carrier, 25% chance of being unaffected/non-carrier (GeneReviews).
Penetrance: full/complete penetrance is assumed for biallelic loss-of-function genotypes, though expressivity (age of onset, symptom severity/spectrum) is markedly variable.
Parental carriers: typically asymptomatic, although abnormal ocular findings have occasionally been reported in heterozygous carriers (GeneReviews).
Genetic anticipation: not a described feature (this is not a repeat-expansion disorder).
Germline mosaicism: not specifically documented in the literature surveyed, though theoretically possible for recessive disorders generally.
Founder effects: Present in specific populations given the Mediterranean/Middle Eastern consanguinity-associated founding cohorts, though SPG11 mutations are broadly heterogeneous worldwide.
Consanguinity: A significant contributing factor historically, as most original description families were consanguineous; disease is nonetheless reported in outbred populations globally.
Carrier frequency: Not explicitly reported as a population-wide statistic in the sources surveyed; can be estimated from the calculated disease prevalence (~1.25/100,000) under Hardy-Weinberg assumptions, but no direct gnomAD-based carrier-frequency figure was retrieved in this search.

Population Demographics

No strong evidence of ethnic-specific enrichment beyond the historical consanguinity-associated founder families (Mediterranean, Middle Eastern, North African); cases are now documented worldwide.
Sex ratio: no sex predilection is described; autosomal recessive inheritance implies equal male:female risk.
Age distribution of affected individuals spans childhood through adulthood given the wide onset range.

10. Diagnostics

Clinical/Laboratory Tests

Routine bloodwork is generally unremarkable; no specific validated circulating biomarker exists.
Electrophysiology: Nerve conduction studies/EMG to document axonal peripheral neuropathy; visual evoked potentials (VEP) and somatosensory evoked potentials (SEP) recommended annually for surveillance (GeneReviews).

Imaging (Key Diagnostic Modality)

Brain MRI is central to diagnosis and shows a highly characteristic pattern: - Thin corpus callosum — present in >90% of individuals (GeneReviews); confirmed at 173/190 (91%) in a large 339-case review (Frontiers in Neurology 2023). - "Ear of the lynx" sign: hyperintense on FLAIR, hypointense on T1, in the periatrial/periventricular white matter — a highly characteristic (though not fully specific) neuroimaging sign. - Periventricular/confluent white matter hyperintensities — 130/158 (82%) in the same cohort. - Cortical atrophy — 55/107 (51%). - Brainstem and cerebellar atrophy also documented; basal ganglia abnormalities have also been reported ("SPG11 mutations cause widespread white matter and basal ganglia abnormalities, but restricted cortical damage," ScienceDirect).

Genetic Testing

First-tier: Single-gene sequence analysis of SPG11, followed by deletion/duplication (CNV) analysis if only one or zero variants are found (since ~10–20% of pathogenic alleles are structural). Alternatively, a multi-gene HSP panel.
Comprehensive: Exome or genome sequencing when the phenotype does not clearly distinguish SPG11 from other complex AR-HSPs (notably SPG15, which is clinically indistinguishable — "No clinical features discriminate between SPG11 & SPG15," per GeneReviews).
Detection sensitivity: sequence analysis ~81%, deletion/duplication analysis ~19% of remaining pathogenic alleles (GeneReviews).

Differential Diagnosis

Key alternative/overlapping diagnoses per GeneReviews: - SPG15 (clinically indistinguishable from SPG11 without genetic testing) - SPG21 (Mast syndrome) - SPG46, SPG47–SPG52 and other complex AR-HSPs with thin corpus callosum - ALS — when lower motor neuron/muscle wasting predominates - Other leukodystrophies/leukoencephalopathies with white matter change and callosal thinning

Clinical Criteria

No formal consensus diagnostic-criteria scoring system (e.g., DSM/ICD-style) exists specifically for SPG11; diagnosis rests on the combination of clinical phenotype + characteristic MRI + confirmatory biallelic molecular genetic testing, per GeneReviews consensus recommendations.

Screening

No newborn screening or population carrier-screening program specifically targets SPG11; carrier testing and prenatal/preimplantation genetic testing are offered on a family-specific basis once the familial pathogenic variants are identified (GeneReviews).

11. Outcome/Prognosis

Life expectancy: Specific quantitative life-expectancy/mortality data were not identified in this search; SPG11 is generally understood as a disabling but not directly life-shortening disease in most reported cohorts (unlike ALS5 presentations, where motor neuron disease severity may carry different prognostic implications).
Functional outcome: Most patients become wheelchair-dependent within 1–2 decades of symptom onset (GeneReviews) — the single most quantified functional/disability outcome in the literature.
Cognitive trajectory: Progressive decline is typical, with a neuropsychology/MRI correlation study showing reaction-time performance correlating with disease progression on longitudinal follow-up (PMC9336101).
Complications: Secondary musculoskeletal complications (contractures, scoliosis) from chronic spasticity if inadequately managed; urinary tract infection risk from neurogenic bladder dysfunction if unmonitored; visual impairment from progressive macular dystrophy in Kjellin-syndrome presentations.
Prognostic factors: Genotype (truncating vs. missense/splice variant) correlates with severity/age of onset — missense/splice variants associate with milder, later-onset disease (GeneReviews).
A dedicated natural history / biomarker study ("Biological course and natural history of hereditary spastic paraplegia type 11 (SPG11)," MDS Abstracts) is explicitly working to establish quantitative biological markers of disease course as a basis for upcoming therapeutic trials — indicating that robust natural-history/prognostic data are still an active area of development rather than fully established.

12. Treatment

No disease-modifying or curative treatment currently exists for SPG11. Management is entirely symptomatic and supportive (GeneReviews):

Pharmacotherapy (Symptomatic)

Spasticity: oral antispastic agents — baclofen, tizanidine; botulinum toxin injections and intrathecal baclofen for severe, treatment-refractory spasticity.
Suggested NCIT term: NCIT:C15986 (Pharmacotherapy), with therapeutic_agent bound to CHEBI (e.g., baclofen CHEBI:2854, tizanidine).
Bladder dysfunction: anticholinergic medications for urinary urgency, guided by urodynamic evaluation.
Psychiatric manifestations: standard psychiatric/psychopharmacologic management per presentation.

Rehabilitative/Supportive Care

Physiotherapy for muscle stretching and contracture prevention (NCIT:C15302, Physical Therapy).
Multidisciplinary coordination among neurology, clinical genetics, physiotherapy, social work, and psychology (GeneReviews).

Investigational / Emerging Approaches

Venglustat (a glucosylceramide synthase inhibitor) is being investigated as a candidate to slow SPG11 progression, in a research program launched March 2025 by Euro-HSP and Life4HSP, based at the Paris Brain Institute under Dr. Frédéric Darios (life4hsp.com). This targets the lysosomal ganglioside/lipid-accumulation mechanistic arm described in §6.
Tideglusib (a GSK3β inhibitor) rescued neurite pathology in SPG11-patient iPSC-derived cortical neurons in a preclinical study, directly implicating the GSK3β-signaling node as a druggable target (PMC6291617).
No SPG11-specific gene therapy trial (viral-vector gene replacement or gene editing) has yet reached clinical testing as of this search (August 2026); gene therapy for HSP overall is at an early stage, exemplified by an unrelated single-patient AAV gene-therapy trial for SPG50 (Nature Medicine, 2024, DOI link) — illustrating the platform/precedent but not yet a SPG11-specific program.
A 2026 review, "Hereditary spastic paraplegia: from decades of therapy to future innovations" (SAGE Journals), frames drug repurposing and early gene-based interventions as the field's emerging disease-modifying strategy for ultra-rare HSP subtypes including SPG11.
Nutritional/dietary intervention: A 2025/2026 scoping review noted no dietary intervention trials have specifically been conducted for SPG11 to date ("Nutritional Approaches in Neurodegenerative Disorders," PMC12609518).

Treatment Outcomes

No randomized controlled trial efficacy data exist yet for any disease-modifying SPG11 therapy; symptomatic-treatment response data (spasticity agents, botulinum toxin, intrathecal baclofen) follow general HSP/spasticity management evidence rather than SPG11-specific trials.

13. Prevention

Primary prevention: Not applicable in the traditional sense (no modifiable environmental cause); the relevant "primary prevention" for SPG11 is reproductive — genetic counseling for at-risk couples/families, ideally initiated before pregnancy, covering recurrence risk (25% per pregnancy for two carrier parents) and reproductive options including prenatal testing and preimplantation genetic testing (GeneReviews).
Secondary prevention: Not a screening-amenable disease at the population level (no newborn or population screening program exists); cascade carrier testing within families once a pathogenic variant is identified is standard practice.
Tertiary prevention (preventing complications in affected individuals): regular physiotherapy to prevent contractures; sphincter-function monitoring to prevent urinary tract infections; scheduled surveillance imaging and electrophysiology to track progression and adjust management (GeneReviews surveillance schedule):
Specialized clinic evaluation every 6 months
Annual brain MRI (corpus callosum, cerebellar/brainstem atrophy, white matter change)
Annual electrophysiologic studies (EMG, VEP, SEP)
Annual visual acuity assessment (given the retinal/macular degeneration risk)
Genetic counseling resources: SPATAX Network, EURO HSP, Spastic Paraplegia Foundation, NINDS HSP information page (GeneReviews resource list).

14. Other Species / Natural Disease

No naturally occurring SPG11 disease has been documented in non-human species (companion animals, livestock, or wildlife) in the literature surveyed — this is a human-specific Mendelian condition without a known veterinary/OMIA counterpart identified in this search. All non-human data derive from engineered/induced models (see §15) rather than naturally occurring animal disease.

15. Model Organisms

Mouse Models

Spg11 knockout mice are the best-characterized model. They develop:
Progressive motor impairment, correlating with accumulation of autofluorescent (lipofuscin-like) material in neurons and progressive neuron loss (PMID:33618608).
Axonal degeneration of cortical motor neurons (source aggregation).
Loss of cortical neurons and Purkinje cells.
In vivo evidence of lysosome depletion and impaired autophagic clearance — degenerating neurons accumulate LAMP1+/p62+ autolysosome-derived material over time due to a defect in autophagic lysosome reformation (ALR), i.e., reduced recycling of lysosomes from autolysosomes (PLOS Genetics, PMC4540459).
Compound Spg11/Zfyve26 (SPG15) knockout mice show even more compromised ALR, underscoring the shared AP-5-complex mechanism ("Mouse models for hereditary spastic paraplegia uncover a role of PI4K2A in autophagic lysosome reformation," PMID:33618608; PMC8632344).
Fidelity: High for the axonal/lysosomal degeneration mechanism and motor phenotype; the mouse model recapitulates progressive upper-motor-neuron axonal pathology and lysosomal dysfunction well, though it does not fully model the human cognitive/intellectual-disability phenotype or the retinal (Kjellin) phenotype.

Zebrafish Models

Depletion of spatacsin in zebrafish impairs motor neuron development, supporting a role for spatacsin in motor neuron differentiation/maintenance and offering a tractable in vivo system for mechanistic and (potentially) drug-screening studies of SPG11-related motor neuropathy (search-aggregated summary).

Cellular / iPSC Models

Patient-derived iPSC cortical neurons (plus a CRISPR-Cas9-engineered SPG11 knockout isogenic control line) recapitulate shortened, less-complex neurites, abnormal membrane-bound structures within neuronal processes, impaired organelle transport, and reduced synaptic vesicle movement — used successfully as a drug-screening platform, identifying the GSK3β inhibitor tideglusib as a rescue compound (PMC6291617).
Broader HSP iPSC-neuron literature (including SPG11 lines) documents impaired neurite outgrowth, increased axonal swellings, and reduced axonal transport as shared, recapitulated disease-specific defects across HSP subtypes modeled by iPSC-derived neurons.

Model Limitations

Mouse and zebrafish models capture the axonal/lysosomal degenerative mechanism and motor phenotype well but do not fully reproduce the human cognitive impairment, thin corpus callosum, or retinal degeneration components of the complex human phenotype — an important human-model-mismatch consideration for any KB entry linking these models to specific pathophysiology nodes.
No SPG11-specific large-animal (canine, feline, non-human primate) model was identified in this search.

Summary of Key Ontology Term Suggestions for KB Curation

Table (click to expand)

Category	Suggested terms
Disease	MONDO (hereditary spastic paraplegia 11, mapped OMIM:604360), OMIM:604360, ORPHA:2822
Gene	HGNC SPG11, hgnc: identifier for spatacsin; also note allelic ALS5/CMT2X phenotype links
Core phenotypes (HP)	HP:0007256/HP:0002061 (spastic paraparesis), HP:0001249 (intellectual disability), HP:0009830 (peripheral neuropathy), HP:0000546 (retinal degeneration), HP:0001251 (ataxia), HP:0001300 (parkinsonism), HP:0002088/related (thin corpus callosum via imaging term), HP:0002650 (scoliosis), HP:0001761 (pes cavus)
Biological process (GO)	Autophagy/autophagosome assembly, endosome organization, lysosome organization, axonal transport
Cellular component (GO)	Lysosome, endosome, axon
Cell types (CL)	Upper motor (corticospinal/pyramidal) neuron, Purkinje cell, peripheral sensory/motor axon-associated cell types
Anatomy (UBERON)	Spinal cord, corpus callosum, cerebellum, retina, peripheral nervous system
Chemicals (CHEBI)	Cholesterol, ganglioside class (lipid-accumulation mechanism); baclofen, tizanidine (symptomatic drugs)
Treatment (NCIT)	NCIT:C15986 (Pharmacotherapy), NCIT:C15302 (Physical Therapy), NCIT:C15240 (Genetic Counseling)

Notable Gaps / Data Not Available

No SPG11-specific validated QoL instrument data (EQ-5D/SF-36) located.
No formal SPG11-specific mortality/life-expectancy statistics located.
No naturally occurring veterinary/animal disease counterpart identified.
No population-level carrier-frequency (gnomAD-derived) figure was retrieved in this search.
No SPG11-specific gene therapy clinical trial yet registered as of August 2026; venglustat (drug-repurposing, small-molecule) is the most advanced disease-modifying investigational approach identified.

Sources

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Table (click to expand)

Outcome	Count
References checked	24
Resolved	8
Unresolved (possible confabulation)	0
Unverifiable	16
Quoted claims checked	2
Quoted claims found in source	2
Quoted claims not found in source	0
Quoted claims with nothing to check against	4
References weighed for topical relevance	8
On topic	7
Off topic	0

Quotes that could not be checked

There was no text to compare these against, so they are neither confirmed nor contradicted:

PMC:PMC4140466: "Dysfunction of spatacsin leads to axonal pathology in SPG11-linked hereditary spastic paraplegia"
The PMC ID service was unreachable, so the quote was not checked
PMC:PMC6291617: "Tideglusib Rescues Neurite Pathology of SPG11 iPSC Derived Cortical Neurons,"
The PMC ID service was unreachable, so the quote was not checked
DOI:10.1177/17562864251406589: "Hereditary spastic paraplegia: from decades of therapy to future innovations"
Reference was skipped, so the quote was not checked
PMC:PMC12609518: "Nutritional Approaches in Neurodegenerative Disorders,"
The PMC ID service was unreachable, so the quote was not checked

8 of 24 references resolved; the rest could not be looked up either way.